Lorbrena (lorlatinib) — United Healthcare
Erdheim-Chester Disease (ECD)
Initial criteria
- Diagnosis of Erdheim-Chester Disease (ECD)
- Disease is symptomatic, relapsed, or refractory
- Disease is ALK-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lorbrena therapy
Approval duration
12 months